Enterovirus 71-Induced Autoimmune Hemolytic Anemia in a Boy

Ploy Pattanakitsakul1, Nongnuch Sirachainan1, Boonrat Tassaneetriphep2, Thongkoon Priengprom2, Pimpun Kijporka3 and Nopporn Apiwattanakul1

1Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. 2Center of Research Excellence in Immunoregulation, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. 3Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

ABSTRACT: Autoimmune hemolytic anemia (AIHA) can be induced by recent or concomitant infections. Many infectious agents are postulated to be associated with this condition. Treatment of infection induced AIHA still varies. This report describes a previously healthy Thai boy who developed AIHA associated with enterovirus-71 infection. He was successfully treated with oral prednisone.

KEYWORDS: AIHA, pediatrics, enterovirus

Introduction

Autoimmune hemolytic anemia (AIHA) is caused by autoantibodies against red blood cell surface antigens inducing hemolysis. The prevalence of AIHA is around 1 per 100 000/year. The severity can range from asymptomatic to life threatening condition. The cause of AIHA in most cases is idiopathic. However, in a small proportion of patients, AIHA can be the consequence of autoimmune disorders (eg, systemic lupus erythematosus, infantile giant cell hepatitis), malignancies (eg, lymphoma, solid tumors) or infections. Infection contributes around 10% of cases. Common infectious organisms that can trigger AIHA include, but not limit to, Mycoplasma pneumoniae (EBV), Cytomegalovirus (CMV), Rubella virus, Influenza virus, Varicella zoster virus, and Severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2). However, cases of Enterovirus-induced AIHA were rare, and cases of Enterovirus 71 (EV71)-induced AIHA have not been reported. Clinical manifestations of enterovirus infection are protean, ranging from non-specific febrile illness to severe myocarditis or severe CNS infection. Common manifestations of EV71 infection are vesicular eruptions involving oral mucosa, palms and soles (hand foot and mouth disease). Rare but severe complications include autonomic dysregulation and brain stem encephalitis. However, hematologic manifestations in patients with EV71 infection have been scarcely described. This report describes a case of an 11-year-old boy who developed AIHA after EV71 infection. Written consent from the patient’s mother was provided before publication of this case.

Case Description

In October, 2020, a previously healthy 11-year-old boy presented with high grade fever, bilateral cervical swelling for 2 days and dark-colored urine for 1 day. There was no history of loose stool, cough, rash, arthritis, dysuria or abnormal bleeding and no history of vaccinations within 1 month prior to admission. He reported vertiginous sensation when walking. On examination, his body weight was 38.4 kg (at 75th percentile) and his height was 144 cm (at 75th percentile). He was fully conscious with moderate pallor and icteric sclerae. Non-tender bilateral cervical lymphadenopathy (sized 1.5-2 cm in diameter) and a tender right cervical lymph node (0.5 cm in diameter) were noted. Hepatosplenomegaly was absent. Cardiovascular, respiratory, and central nervous system examinations were unremarkable. The patient had no prior history of anemia or jaundice. Family history was unremarkable for any underlying hematological diseases. He denied taking any medications prior to the onset of his symptoms.

His complete blood count showed hemoglobin (Hb) 7 g/dL, hematocrit (Hct) 20.9%, white blood count 32 710/mm3, platelet count 493 000/mm3, reticulocytes 3.4%, D-dimer 16 027 ng/mL, haptoglobin 0.05 mg/mL (normal range, 0.32-1.97), lactate dehydrogenase (LDH) 1682 U/L, total bilirubin 6.4 mg/dL with direct bilirubin level of 0.5 mg/dL. G6PD screening was normal. Serum electrolytes were within normal range (sodium 132, potassium 3.91, chloride 103, carbon dioxide 18.6 mmole/L). Blood urea nitrogen and serum creatinine were 23 and 0.66 mg/dL, respectively. Liver function test revealed alkaline phosphatase (ALP) 284, aspartate aminotransferase (AST) 104, alanine aminotransferase (ALT) 14 and gamma glutamyl transferase (γGT) 23 U/L. Serum protein and albumin were 88.2 and 35.5 g/L, respectively. Peripheral blood smear showed microsperoocyte 1-2+ with few polychromasia and no schistocytes (Figure 1). Red blood cell autoagglutination was not significantly noticed. Urinalysis showed dark-colored urine, positive 4+ of protein.
negative glucose, negative bilirubin, marked positive of blood with 0-1/HPF of red blood cells. This indicated hemoglobinuria supporting the evidence of intravascular hemolysis. Direct Coombs test was positive 2+ for C3c, positive 4+ for C3d, but negative for IgG, IgM, and IgA. AIHA was diagnosed. In order to find the etiology of AIHA, associated infectious diseases were sought. *Mycoplasma pneumoniae* antibody test (combined IgM and IgG detection by gelatin particle agglutination method; SERODIA®) was negative. EBV serology test (by lateral flow technique; vircell company) showed negative viral capsid antigen IgM, positive viral capsid antigen IgG, and positive Ebstein-Barr nuclear antigen (EBNA) IgG, indicating remote EBV infection. Blood and urine cultures were sterile. A multiplex PCR testing (QIAGEN) performed on nasopharyngeal swab was positive for rhinovirus/enterovirus. Because enterovirus infection was prevalent around the time of the patient’s illness, enterovirus infection was suspected. The microneutralization test against EV71 in serum obtained on the admission day showed significantly elevated titers of neutralizing antibody at 1:640, while the neutralizing antibody titer against coxsackievirus A16 (CA16) was <1:10. The technique of microneutralization test is described in Appendix 1. Since there was no local transmission of SARS-CoV2 in Thailand at that time, screening for SARS-CoV2 was not performed.

Given his severe symptoms as hemoglobin level being 7 g/dL with vertiginous symptoms which may be attributed by anemia and specific type of AIHA could not be definitely determined at that time, he was treated with 60 mg per day of oral prednisolone (1.5 mg/kg/day), 2 units of red cell transfusion, intravenous fluid hydration and other supportive treatment. Fever subsided within a day and hemoglobinuria disappeared 2 days after initiation of treatment. Hemoglobin increased from 7 to 14.1 g/dL, and reticulocyte count decrease from maximum of 6% to 1.9% after 35 days of first presentation. Prednisolone was continued and gradually tapered to complete a total of 10 weeks. At 10-week follow-up visit, the patient’s hemoglobin level was 14.1 g/dL with negative Coombs test and normalization of reticulocyte count and LDH level (Table 1). The clinical course of the patient is demonstrated in Figure 2.

**Discussion**

This previously healthy boy presented with acute febrile illness, cervical lymphadenopathy and pallor. The nasopharyngeal sample was positive for Rhino/Enterovirus and microneutralization test was strongly positive for Enterovirus 71. Autoimmune hemolytic anemia was concurrently diagnosed based on clinical presentation of anemia and laboratory findings of reticulocytosis, increased LDH level, indirect hyperbilirubinemia, low haptoglobin and positive direct Coombs test. To our knowledge, this is the first reported case of AIHA associated with EV71 infection. This report demonstrates that hematological complication can follow or be associated with EV71 infection. In addition to monitoring of cardiopulmonary and neurological complications following EV71 infection, monitoring of hematological complications may also be necessary.

AIHA can be categorized into many types. The types and etiology of AIHA have been recently reviewed.\(^{20,21}\) In order to determine the type of AIHA, additional tests are needed.\(^{20,22}\) Since we could not perform cold agglutinin titer to rule out cold agglutinin disease or cold agglutinin syndrome (CAS) and Donath–Landsteiner’s test to rule out paroxysmal cold hemoglobinuria (PCH),\(^{20}\) we could not determine the exact phenotype of AIHA in this patient. This patient had intravascular hemolysis supported by the evidence of positive urine hemoglobin and low blood haptoglobin level. The direct Coombs test was positive for complement but negative for IgG and IgM. PCH has been proposed to be associated with infections in children.\(^{20,22,23}\) These pieces of evidence made PCH the most likely diagnosis in this patient. Donath–Landsteiner’s test is indeed needed to confirm this diagnosis. The fact that the patient had intravascular hemolysis and very few red blood cell agglutination in peripheral blood smear disfavors the diagnosis of CAS. Nasal swab multiplex PCR testing for respiratory viruses and serological tests for Ebstein Barr virus and *Mycoplasma pneumoniae* were performed because of their common association with AIHA. In this case, the respiratory virus PCR test showed evidence of rhinovirus/enterovirus infection even though the patient had not had clinical presentation of hand foot and mouth disease. Enterovirus infection may manifest as non-specific febrile illness or may be asymptomatic.\(^{25}\) We believe that fever and swollen cervical lymph nodes might be the clinical manifestations of EV71 infection in this case. Evidence of recent EV71 infection was established by a significant rise in serum neutralization antibody titer against EV71. The neutralizing antibody against enterovirus can be used to identify enterovirus to species level\(^{26}\) and it was used to confirm
the diagnosis of recent EV71 infection in this case. In our case, we then postulated that AIHA was triggered by the EV71 infection according to this temporal relationship.

In general, EV71 is an important pathogen of hand foot and mouth disease and herpangina. The common complication of EV71 is aseptic meningitis, poliomyelitis-like paralysis, brain-stem encephalitis, autonomic dysregulation and pulmonary edema. However, its role as a cause of hematologic complications is rare. There was a report of hemolytic-uremic syndrome associated with enterovirus infection, while a few cases of enterovirus infection induced hemolytic anemia have been reported in the literature. A review of literature reporting a total case of 265 children with AIHA showed that 10% of cases were post-infectious and only one case was from enterovirus. However, its role as a cause of hematologic complications is rare. There was a report of hemolytic-uremic syndrome associated with enterovirus infection, while a few cases of enterovirus infection induced hemolytic anemia have been reported in the literature. A review of literature reporting a total case of 265 children with AIHA showed that 10% of cases were post-infectious and only one case was from enterovirus. However, detailed descriptions of the case were not available. Marxgut et al reported another case of a girl presenting with enterovirus-related AIHA but the detailed serotype of the etiologic virus and type of AIHA were not mentioned.

In addition, this reported case was suspected to have underlying primary immune deficiency which was cured by bone marrow transplantation. To the best of our knowledge, our case is the first case of AIHA following definite EV71 infection.

Although the mechanism of EV71 infection induced AIHA remains unclear, the production of autoantibodies recognizing erythrocyte antigen has been considered. It is postulated that virus can modify host immune responses such as increasing macrophage ability to phagocytose antibody-coated erythrocytes leading to hemolysis, enhancing the pathogenicity of pre-existing autoantibodies, and exacerbating erythrophagocytosis through macrophage activation by gamma-interferon.

The management of infection associated AIHA was based on the etiologies and severity of anemia. Most patients can be managed supportively with appropriate antimicrobials and transfusion for symptomatic anemia. Some patients received corticosteroid for severe persistent hemolysis. In a review of 26 pediatric cases of AIHA, 81% of patients responded well to oral corticosteroid therapy. Currently, monoclonal antibodies

| Table 1. Laboratory data of the patient. |
|----------------------------------------|
| HB (g/DL) RETICULOCYTE (%) TOTAL WBC (MM³) DIFFERENTIAL WBC (%) PLATELET COUNT (MM³) LDH (IU/L) DIRECT COOMBS DIRECT ERYTHROCYTES (MMOLES/L) DIRECT BUN/CR (MG/DL) LFT (U/L) |
| Day 1 | 7 3.4 32710 | N 78 L 12 M 4 Band 2 Myelo 2 Blast 2 | 493000 | 1682 Positive | Na 132 K 3.91 Cl 103 CO₂ 18.6 | 23/0.66 ALP 234 AST 104 ALT 14 γGT 23 |
| Day 2 | 6.2 4.7 20450 | N 79 L 14 M 6 B 1 | 446000 | | Na 139 K 4.87 Cl 111 CO₂ 19.9 | 17/0.52 |
| Day 3 | 7.6 4.3 20939 | N 79 L 14 M 7 | 458000 | 1681 | | |
| Day 4 | 7.5 6 17140 | N 72 L 24 M 3 Myelo 1 | 474000 | 1100 | Na 139 K 3.59 Cl 108 CO₂ 22.9 | 12/0.46 ALP 166 AST 25 ALT 16 γGT 24 |
| Day 14 | 12.2 5.7 11860 | N 84 L 11 M 5 | 499000 | 282 Weakly positive | | |
| Day 35 | 14.1 1.9 11600 | N 75 L 20 M 4 E 1 | 402000 | 285 | | |
| Day 77 | 14.1 1.1 6500 | N 30 L 51 M 11 E 4 B 1 Atyp L 3 | 343000 | 288 Negative | | |

Abbreviations: γGT, gamma glutamyl transferase; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Atyp L, atypical lymphocyte; B, basophil; BUN, blood urea nitrogen; Cl, chloride; CO₂, carbon dioxide; Cr, creatinine; E, eosinophil; g/dL, gram per deciliter; Hb, haemoglobin; IU/L, international unit per liter; K, potassium; L, lymphocyte; LDH, lactate dehydrogenase; LFT, liver function test; mg/dL, milligram per deciliter; mm³, cubic millimetre; M, monocyte; Myelo, myelocyte; N, neutrophil; Na, sodium; U/L, unit per liter; WBC, white blood count. Day1 represents the day of admission.
targeting specific effector cells or molecules responsible for AIHA are being developed and successful treatment with these monoclonal antibodies have been increasingly reported. For example, complement can be responsible for opsonization of red blood cells leading to phagocytosis of these cells, complement inhibition with eculizumab was reported to be effective in treatment of PCH in one case report. Although PCH was the most likely diagnosis in this patient and corticosteroid efficacy in PCH is uncertain, this patient received prednisone upon AIHA diagnosis because the type of AIHA could not be determined initially and the patient had very low hemoglobin level and anemic symptom. Steroid could be considered in cases with severe PCH. The patient rapidly recovered upon treatment though PCH may also spontaneously recover with only supportive treatment. The patient received 10 weeks of prednisolone without adverse events.

In conclusion, this reported case demonstrate the association of EV71 infection and AIHA in a previously healthy young child. EV71 infection was confirmed by microneutralization test. Apart from known neurological and cardiopulmonary complications, EV71 infection can be associated with AIHA. EV71 should be considered as another possible cause of virus-induced AIHA in any patients presenting with hemolytic anemia, especially during the season of EV71 outbreak.

**Acknowledgements**
We would like to thank Ms. Jantip Saelee for laboratory assistance.

**Author Contributions**
PP and NA drafted the manuscript. PP, NS and NA took care of the patient. BT, TP and PK provided the laboratory data.

**ORCID iD**
Nopporn Apiwattanakul [https://orcid.org/0000-0003-1833-5127](https://orcid.org/0000-0003-1833-5127)

**Supplemental Material**
Supplemental material for this article is available online.

**REFERENCES**
1. Naithani R, Agrawal N, Mahapatra M, Kumar R, Pati HP, Choudhry VP. Autoimmune hemolytic anemia in children. *Pediatr Hematol Oncol*. 2007;24:309-315.
2. Domiciano DS, Shinjo SK. Autoimmune hemolytic anemia in systemic lupus erythematosus: association with thrombocytopenia. *Clin Rheumatol*. 2010;29:1427-1431.
3. Poddighe D, Madiyeva A, Talipova D, Umirbekova B. Infantile giant cell hepatitis with autoimmune hemolytic anemia. *World J Hepatol*. 2021;13:411-420.
4. Barcellini W, Fattizzo B. The changing landscape of autoimmune hemolytic anemia. Front Immunol. 2020;11:946.
5. Burley NB, Dy PS, Hande S, Kalantri S, Mohindroo C, Miller K. Autoimmune hemolytic anemia as presenting symptom of Hodgkin Lymphoma. Case Rep Hematol. 2021;2021:5580821.
6. Portenier B, Lechner K, Kornek G. Autoimmune hemolytic anemia as a paraneoplastic phenomenon in solid tumors: a critical analysis of 52 cases reported in the literature. Wien Klin Wochenschr. 2010;122:229-236.
7. Aladjidi N, Leverger G, Leblanc T, et al. New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children. Haematologica. 2011;96:655-663.
8. Khan FY, Ayyasim M. Mycoplasma pneumoniae associated with chronic autoimmune hemolytic anemia: case report and literature review. Braz J Infect Dis. 2009;13:77-79.
9. Martinez Nadal S, Alzorta Loyola I, Estella Aguado J, Rives Sola S, Toll Costa T. [Autoimmune hemolytic anemia with complement-positive direct antiglobulin test]. An Pediatr. 2005;59:294-296.
10. Taglietti F, Drapeau CM, Grilli E, et al. Hemolytic anemia due to acute cytomegalovirus infection in an immunocompetent adult: a case report and review of the literature. J Med Case Rep. 2010;4:334.
11. Yoneda S, Yoshikawa M, Yamane Y, Nishimura K, Fukuji H. A case of rubella complicated by hemolytic anemia. Kansenshogaku Zasshi. 2000;74:724-728.
12. Shizuma T. A case of autoimmune hemolytic anemia caused by type A influenza infection in a patient with alcoholic liver cirrhosis. Kansenshogaku Zasshi. 2010;84:296-299.
13. Kumar KJ, Kumar HC, Manjunath VG, Arun V. Autoimmune hemolytic anemia due to varicella infection. Iran J Pediatr. 2013;23:491-492.
14. Capes A, Bailly S, Hantspon P, Gerard L, Laterre PF. COVID-19 infection associated with autoimmune hemolytic anemia. Ann Hematol. 2020;99:1679-1680.
15. Hindlelend F, Yonal-Hindlelend I, Akar E, Yesilbag Z, Kart-Yasar K. Severe autoimmune hemolytic anemia in COVID-19 infection, safely treated with steroids. Mediterr J Hematol Infect Dis. 2022;14:e26051.
16. Marxgut M, Adjaoud D, Aladjidi N, Armari C, Marxgut L, Rubio A. Generalized verrucosis revealing a life-threatening and unlabeled T-Cell lymphopenia associated with autoimmune hemolytic anemia: a case report and review of literature. J Pediatr Hematol Oncol. 2020;42:e745-e749.
17. Chen JH, Li T, Wang ET, Chiu NC, Wu KB. An analysis of Cossackie B3 enterovirus outbreaks in Taiwan in 2005. Paper presented at: The Fourth TEPHINET Southeast Asia and Western Pacific Bi-regional Scientific Conference; 2007.
18. Verma NA, Zheng XT, Harris MU, et al. Outbreak of life-threatening coxsackievirus B1 myocarditis in neonates. Clin Infect Dis. 2009;49:759-763.
19. Nayak G, Bhuyan SK, Bhuyan R, Sahu A, Kar D, Kumar A. Global emergence of Enterovirus 71: a systematic review. Biorxiv Unloc J Basic Appl Sci. 2022;11:78.
20. Berentsen S, Barcellini W. Autoimmune hemolytic anemia. New Engl J Med. 2021;385:1407-1419.
21. Hill QA, Stamps R, Massey E, Grainger JD, Provan D, Hill A. The diagnosis and management of primary autoimmune haemolytic anaemia. Br J Haematol. 2017;176:395-411.
22. Hill QA, Hill A, Berentsen S. Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment. Blood Adv. 2019;3:1897-1906.
23. Göttse B, Salama A, Mueller-Eckhardt C. Donath-Landsteiner autoimmune hemolytic anemia in children. A study of 22 cases. Vox Sang. 1990;58:281-286.
24. Shanbhag S, Spivak J. Paroxysmal cold hemoglobinuria. Hematol Oncol Clin North Am. 2015;29:473-478.
25. Sun B, Gao J, Chen D, Dou H, Zhu C. Study on the excessive infection of hand, foot and mouth disease (HFMD) virus in children. Pract Prev Med. 2014;21:914-916.
26. Nijhuis B, van Maarseveen N, Schuurman R, et al. Rapid and sensitive routine detection of all members of the genus enterovirus in different clinical specimens by real-time PCR. J Clin Microbiol. 2002;40:3666-3670.
27. McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance. PEMS Microblad Rev. 2002;26:91-107.
28. Lee MD, Tzen CY, Lin CC, Huang FY, Liu HC, Tsai JD. Hemolytic uremic syndrome caused by enteroviral infection. Pediatr Neonatol. 2013;54:207-210.
29. Meite M, Léonard S, Idrissi ME, Izui S, Masson PL, Coutelier JP. Exacerbation of autoantibody-mediated hemolytic anemia by viral infection. J Virol. 2000;74:6045-6049.
30. Coutelier JP, Detalle I., Muaaji A, Meite M, Izui S. Two-step mechanism of virus-induced autoimmune hemolytic anemia. Ann N Y Acad Sci. 2007;1109:151-157.
31. Hill QA, Stamps R, Massey E, Grainger JD, Provan D, Hill A. Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia. Br J Haematol. 2017;177:208-220.
32. Xiao Z, Murakhovskaya I. Development of new drugs for autoimmune hemolytic anemia. Pharmaceutics. 2022;14: doi: 10.3390/pharmaceutics1405033. 2022;14:e26051.
33. Tahhan F, Huynt B, Xi X. Novel monoclonal antibody therapy in a patient with treatment-refractory warm autoimmune hemolytic anemia. Cancers. 2022;14:e26051.
34. Tao Y, Han J, Li Y. Autoimmune hemolytic anemia in patients with relapsed Hodgkin’s lymphoma after treatment with pembrolizumab, a monoclonal antibody against programmed death receptor-1. Investig New Drugs. 2022;40:854-857.
35. Lau-Braunhut SA, Stone H, Collins G, Berentsen S, Braun BS, Zinter MS. Paroxysmal cold hemoglobinuria successfully treated with complement inhibition. Blood Adv. 2019;3:3575-3578.
36. Pasquelle R, Giannotta JA, Barcellini W, Fattizzo B. Bortezomib in autoimmune hemolytic anemia and beyond. Ther Adv Hematol. 2021;12:20406027211046428.
37. Sokol RJ, Brooker DJ, Stamps R. Erythropoiesis: Paroxysmal cold haemoglobinuria: A clinico-pathological study of patients with a positive Donath-Landsteiner test. Hematology. 1999;4:137-164.